Literature DB >> 18539367

Saccharide/protein conjugate vaccines for Bordetella species: preparation of saccharide, development of new conjugation procedures, and physico-chemical and immunological characterization of the conjugates.

Joanna Kubler-Kielb1, Evgeny Vinogradov, Gil Ben-Menachem, Vince Pozsgay, John B Robbins, Rachel Schneerson.   

Abstract

Bordetellae are Gram-negative bacilli causing respiratory tract infections of mammals and birds. Clinically important are B. pertussis, B. parapertussis and B. bronchiseptica. B. pertussis vaccines have been successful in preventing pertussis in infants and children. Veterinary vaccines against B. bronchiseptica are available, but their efficacy and mode of action are not established. There is no vaccine against B. parapertussis. Based on the concept that immunity to non-capsulated Gram-negative bacteria may be conferred by serum IgG anti-LPS we studied chemical, serological and immunological properties of the O-specific polysaccharides (O-SP) of B. bronchiseptica and B. parapertussis obtained by different degradation procedures. One type of the B. parapertussis and two types of B. bronchiseptica O-SP were recognized based on the structure of their non-reducing end saccharide; no cross-reaction between the two B. bronchiseptica types was observed. Competitive inhibition assays showed the immunodominance of the non-reducing end of these O-SP. Conjugates of B. bronchiseptica and B. parapertussis O-SP were prepared by two methods: using the anhydro-Kdo residue exposed by mild acid hydrolysis of the LPS or the 2,5-anhydromannose residue exposed by deamination of the core glucosamine of the LPS, for binding to an aminooxylated protein. Both coupling methods were carried out at a neutral pH, room temperature, and in a short time. All conjugates, injected as saline solutions at a fraction of an estimated human dose, induced antibodies in mice to the homologous O-SP. These methodologies can be applied to prepare O-SP-based vaccines against other Gram-negative bacteria.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18539367      PMCID: PMC2518646          DOI: 10.1016/j.vaccine.2008.04.079

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  44 in total

1.  Proteins containing reductively aminated disaccharides. Synthesis and chemical characterization.

Authors:  B A Schwartz; G R Gray
Journal:  Arch Biochem Biophys       Date:  1977-06       Impact factor: 4.013

2.  Bordetella parapertussis and Bordetella bronchiseptica contain transcriptionally silent pertussis toxin genes.

Authors:  B Aricò; R Rappuoli
Journal:  J Bacteriol       Date:  1987-06       Impact factor: 3.490

3.  Xanthomonas sinensis cell wall lipopolysaccharide. I. Isolation of 4,7-anhydro- and 4,8-anhydro-3-deoxy-octulosonic acid following acid hydrolysis of Xanthomonas sinensis lipopolysaccharide.

Authors:  W A Volk; N L Salomonsky; D Hunt
Journal:  J Biol Chem       Date:  1972-06-25       Impact factor: 5.157

4.  Nasal and tracheal resistance of swine against reinfection by Bordetella bronchiseptica.

Authors:  D L Harris; W P Switzer
Journal:  Am J Vet Res       Date:  1969-07       Impact factor: 1.156

Review 5.  Biology of Bordetella bronchiseptica.

Authors:  R A Goodnow
Journal:  Microbiol Rev       Date:  1980-12

6.  Vaccination against Bordetella bronchiseptica infection in dogs using a heat-killed bacterial vaccine.

Authors:  I A McCandlish; H Thompson; N G Wright
Journal:  Res Vet Sci       Date:  1978-07       Impact factor: 2.534

7.  Poly(gamma-D-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: a potential addition to the anthrax vaccine.

Authors:  Rachel Schneerson; Joanna Kubler-Kielb; Teh-Yung Liu; Zhong-Dong Dai; Stephen H Leppla; Alfred Yergey; Peter Backlund; Joseph Shiloach; Fathy Majadly; John B Robbins
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-11       Impact factor: 11.205

8.  Nucleotide sequence homology to pertussis toxin gene in Bordetella bronchiseptica and Bordetella parapertussis.

Authors:  K S Marchitto; S G Smith; C Locht; J M Keith
Journal:  Infect Immun       Date:  1987-03       Impact factor: 3.441

9.  Monoclonal antibody against pertussis toxin: effect on toxin activity and pertussis infections.

Authors:  H Sato; A Ito; J Chiba; Y Sato
Journal:  Infect Immun       Date:  1984-11       Impact factor: 3.441

10.  Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates.

Authors:  R Schneerson; O Barrera; A Sutton; J B Robbins
Journal:  J Exp Med       Date:  1980-08-01       Impact factor: 14.307

View more
  10 in total

1.  Determination of the glycation sites of Bacillus anthracis neoglycoconjugate vaccine by MALDI-TOF/TOF-CID-MS/MS and LC-ESI-QqTOF-tandem mass spectrometry.

Authors:  Farid Jahouh; Shu-jie Hou; Pavol Kováč; Joseph H Banoub
Journal:  J Mass Spectrom       Date:  2011-10       Impact factor: 1.982

2.  Evidence for horizontal gene transfer of two antigenically distinct O antigens in Bordetella bronchiseptica.

Authors:  Anne M Buboltz; Tracy L Nicholson; Alexia T Karanikas; Andrew Preston; Eric T Harvill
Journal:  Infect Immun       Date:  2009-06-15       Impact factor: 3.441

3.  A scalable method for O-antigen purification applied to various Salmonella serovars.

Authors:  F Micoli; S Rondini; M Gavini; I Pisoni; L Lanzilao; A M Colucci; C Giannelli; F Pippi; L Sollai; V Pinto; F Berti; C A MacLennan; L B Martin; A Saul
Journal:  Anal Biochem       Date:  2012-11-07       Impact factor: 3.365

4.  Toward a new vaccine for pertussis.

Authors:  John B Robbins; Rachel Schneerson; Joanna Kubler-Kielb; Jerry M Keith; Birger Trollfors; Evgeny Vinogradov; Joseph Shiloach
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-20       Impact factor: 11.205

5.  Oligosaccharide conjugates of Bordetella pertussis and bronchiseptica induce bactericidal antibodies, an addition to pertussis vaccine.

Authors:  Joanna Kubler-Kielb; Evgeny Vinogradov; Teresa Lagergård; Ariel Ginzberg; Jerry D King; Andrew Preston; Duncan J Maskell; Vince Pozsgay; Jerry M Keith; John B Robbins; Rachel Schneerson
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-22       Impact factor: 11.205

6.  Synthesis, characterization, and immunogenicity in mice of Shigella sonnei O-specific oligosaccharide-core-protein conjugates.

Authors:  John B Robbins; Joanna Kubler-Kielb; Evguenii Vinogradov; Christopher Mocca; Vince Pozsgay; Joseph Shiloach; Rachel Schneerson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-03       Impact factor: 11.205

7.  The O antigen is a critical antigen for the development of a protective immune response to Bordetella parapertussis.

Authors:  Xuqing Zhang; Elizabeth M Goebel; Maria Eugenia Rodríguez; Andrew Preston; Eric T Harvill
Journal:  Infect Immun       Date:  2009-09-08       Impact factor: 3.441

8.  Structural characterization of Bordetella parapertussis lipid A.

Authors:  Asmaa El Hamidi; Alexey Novikov; Doris Karibian; Malcolm B Perry; Martine Caroff
Journal:  J Lipid Res       Date:  2008-11-17       Impact factor: 5.922

9.  Horizontally acquired divergent O-antigen contributes to escape from cross-immunity in the classical bordetellae.

Authors:  Sara E Hester; Jihye Park; Laura L Goodfield; Heather A Feaga; Andrew Preston; Eric T Harvill
Journal:  BMC Evol Biol       Date:  2013-09-25       Impact factor: 3.260

10.  Constructing conjugate vaccine against Salmonella Typhimurium using lipid-A free lipopolysaccharide.

Authors:  Tzu-Wei Chiu; Chi-Jiun Peng; Ming-Cheng Chen; Mei-Hua Hsu; Yi-Hua Liang; Cheng-Hsun Chiu; Jim-Min Fang; Yuan Chuan Lee
Journal:  J Biomed Sci       Date:  2020-08-24       Impact factor: 8.410

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.